Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 02/12 04:14:59 pm
7.28 USD   +2.68%
02/04 IMMUNOGEN : and Merck Establish Collaboration for Clinical Evaluatio..
02/03 IMMUNOGEN : Announces Webcasts of Presentations at Upcoming Investor..
01/29 IMMUNOGEN : reports 2Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,577,366,487,7
Operating income (EBITDA)-68,4-66,9-54,4-94,1-102-97,5
Operating profit (EBIT)-73,0-71,5-59,9-102-123-94,4
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-124-152-143
P/E ratio-19,1-14,3-20,3-4,96-4,45-4,88
EPS ( $ )-0,87-0,83-0,71-1,43-1,60-1,45
Dividend per Share ( $ )------
Yield------
Reference price ( $ )16.5911.8514.387.097.097.09
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt-----27,4
Finance19514227877,272,4-
Operating income (EBITDA)-68,4-66,9-54,4-94,1-102-97,5
Leverage
(Debt/EBITDA)
------0,28x
Capital Expenditure3,778,187,4313,514,415,2
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $-0,71 $-0,70 $-1,65 $
Cash Flow per Share-0,72 $-0,63 $-0,64 $-1,34 $-1,47 $-1,37 $
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 617 M$ -
Entreprise Value (EV) 540 M$ 545 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS)
Capitalization / Revenue 7,99x 9,30x
EV / Revenue 6,99x 8,21x
EV / EBITDA -5,74x -5,32x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -9,99x -10,1x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -132% -185%
operating Leverage (Delta EBIT / Delta Sales) -7,20x -1,49x
Net Margin (Net Profit / Revenue) -161% -229%
ROA (Net Profit / Asset) -45,9% -
ROE (Net Profit / Equities) 1 469% 483%
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   17,5% 21,6%
Cash Flow / Sales -151% -193%
Capital Intensity (Assets / Sales) 3,51x -
Financial Leverage (Net Debt / EBITDA) 0,82x 0,71x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend